A detailed history of Dixon Hubard Feinour & Brown Inc transactions in Amgen Inc stock. As of the latest transaction made, Dixon Hubard Feinour & Brown Inc holds 4,854 shares of AMGN stock, worth $1.36 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
4,854
Previous 4,819 0.73%
Holding current value
$1.36 Million
Previous $1.17 Million 1.37%
% of portfolio
0.14%
Previous 0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 22, 2022

BUY
$230.71 - $256.74 $8,074 - $8,985
35 Added 0.73%
4,854 $1.18 Million
Q1 2022

May 09, 2022

BUY
$219.27 - $242.57 $21,927 - $24,257
100 Added 2.12%
4,819 $1.17 Million
Q4 2021

Jan 10, 2022

BUY
$198.88 - $227.6 $687,727 - $787,040
3,458 Added 274.23%
4,719 $1.06 Million
Q3 2021

Oct 19, 2021

BUY
$212.27 - $248.7 $64,317 - $75,356
303 Added 31.63%
1,261 $268,000
Q2 2021

Aug 23, 2021

SELL
$233.58 - $259.14 $58,862 - $65,303
-252 Reduced 20.83%
958 $234,000
Q2 2020

Jul 31, 2020

SELL
$197.81 - $242.74 $13,055 - $16,020
-66 Reduced 5.17%
1,210 $309,000
Q1 2020

May 15, 2020

SELL
$182.24 - $241.7 $20,957 - $27,795
-115 Reduced 8.27%
1,276 $259,000
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $56,763 - $72,960
300 Added 27.5%
1,391 $335,000
Q3 2019

Nov 13, 2019

SELL
$174.11 - $208.62 $1,044 - $1,251
-6 Reduced 0.55%
1,091 $211,000
Q2 2019

Aug 14, 2019

SELL
$166.7 - $195.41 $19,837 - $23,253
-119 Reduced 9.79%
1,097 $202,000
Q1 2019

May 17, 2019

BUY
$180.87 - $203.88 $23,693 - $26,708
131 Added 12.07%
1,216 $231,000
Q2 2018

Jul 25, 2018

BUY
$166.05 - $186.51 $180,164 - $202,363
1,085 New
1,085 $200,000
Q4 2017

Feb 20, 2018

SELL
$168.79 - $188.59 $5.91 Million - $6.61 Million
-35,027 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$167.29 - $191.0 $5.86 Million - $6.69 Million
35,027
35,027 $6.53 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Dixon Hubard Feinour & Brown Inc Portfolio

Follow Dixon Hubard Feinour & Brown Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dixon Hubard Feinour & Brown Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dixon Hubard Feinour & Brown Inc with notifications on news.